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Second-Line Chemotherapy for Advanced Non-small Cell Lung Cancer
Original Article
Purpose
There is no regimen that is strongly recommended for more than second-line treatment.
We investigated the efficacy and safety of platinum/vinorelbine as more than second-line
treatment.
Materials and Methods
We selected patients with advanced non-small cell lung cancer (NSCLC) who received treat-
ment with platinum/vinorelbine at Chungnam National University Hospital from August
2001 to December 2013. The primary end point was the response rate, and secondary end
points were progression-free survival (PFS), overall survival (OS), and toxicity.
Results
Thirty-five patients were enrolled. Response rate was 22.9% (complete response, 0 patients
[0%]; partial response, eight patients [22.9%]; stable disease, 10 patients [28.6%]; progres-
sive disease, 14 patients [40.0%]). A significantly higher response rate was observed for
patients who had responded to previous chemotherapy than for those who did not (34.8%
[8/23] vs. 0% [0/12], p=0.020). The median PFS was 4 months (range, 1 to 21 months).
Patients with adenocarcinoma and non-smokers had a significantly longer PFS than patients
with non-adenocarcinoma and smokers (5 months vs. 2 months, p=0.007; 4.5 months vs. 
2 months, p=0.046, respectively). The median OS was 10 months (range, 1 to 41 months).
Patients with good performance status and non-smokers had a significantly longer OS than
patients with poor performance status and smokers (14 months vs. 4 months, p=0.02;
18.5 months vs. 6 months, p=0.049, respectively). The main serious adverse event (grade
3 or 4) was neutropenia (15 events, 13.3%) in a total of 113 cycles.
Conclusion
Platinum/vinorelbine was effective as more than second-line chemotherapy, and the toxicity
was tolerable, in patients with advanced NSCLC.
Key words
Non-small-cell lung carcinoma, Third-line treatment, Drug therapy
Introduction
Despite recent advances in treatment of non-small-cell
lung cancer (NSCLC), almost all patients with metastatic or
unresectable cases of NSCLC inevitably experience disease
progression [1]. In addition, as supportive care of patients
with advanced cancer is developing, an increasing number
of patients with advanced NSCLC who are treated with
chemotherapy eventually receive therapies beyond second-
line chemotherapy [2].
There are several standard first-line therapies for patients
with advanced NSCLC: platinum-based doublet combina-
tion chemotherapy, epidermal growth factor receptor (EGFR)
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tyrosine kinase inhibitors in patients with an EGFRmutation,
or crizotinib for anaplastic lymphoma kinase (ALK)–positive
patients [3]. Second-line chemotherapy using single-agent
docetaxel, pemetrexed, or erlotinib is acceptable for patients
with advanced NSCLC, with adequate performance status,
and in whom the disease has progressed during or after first-
line therapy [4-7]. However, there are no regimens that are
strongly recommended as a third or higher line of treatment.
In general, agents which have not already been administered
are recommended as third-line therapies for patients with
good performance.
Platinum/vinorelbine was one of the regimens recom-
mended as a front-line treatment; its survival data and 
response rates are equivalent to those of cisplatin/gemc-
itabine [8,9]. However, no data on the use of platinum/
vinorelbine beyond their use as a second-line therapy have
been reported. Therefore, the aim of this retrospective analy-
sis was to investigate the efficacy and safety of platinum/
vinorelbine as a third or higher line of treatment.
Materials and Methods
1. Eligibility
Eligible patients were aged ! 18 years with a histologically
confirmed diagnosis of advanced NSCLC and had experi-
enced disease progression after second-line treatment. 
Patients were required to have an Eastern Cooperative 
Oncology Group (ECOG) performance status of 0-2 and 
adequate bone marrow, renal, and liver functions (absolute
neutrophil count ! 1,500/µL, platelet ! 100,000/µL, hemoglo-
bin ! 9.0 g/dL, serum creatinine and bilirubin < 1.5-fold the
upper limit of normal and aspartate aminotransferase and
alanine aminotransferase < 3-fold the upper limit of normal).
Patients were treated with platinum/vinorelbine as the third
or higher line of treatment at Chungnam National University
Hospital from August of 2001 to December of 2013. 
The medical records of the enrolled patients were revie-
wed retrospectively. The following data were evaluated: 
performance status based on the ECOG performance scale,
histology, previous chemotherapy regimens, clinical stage at
the time of diagnosis, dose intensity of chemotherapeutic
agents, and objective response rate and survival data. The
study protocol was approved by the local institutional 
review board.
2. Treatment 
Patients received cisplatin 60 mg/m2 or carboplatin at an
area under the curve of 5, on day 1, plus vinorelbine 
25 mg/m2 on days 1 and 8, every 3 weeks. Treatment was
sustained up to 6 cycles but was discontinued in patients
who developed progressive disease or unacceptable toxicity.
3. Endpoints
The primary endpoint of this study was to evaluate the
overall response rate of platinum/vinorelbine; the secondary
endpoints were disease control rate, progression-free 
survival (PFS), overall survival (OS), and toxicity. The best
response to chemotherapy was classified according to the 
Response Evaluation Criteria in Solid Tumor Criteria ver. 1.1.
The disease control rate was defined as the addition of an 
objective response and stable disease rates. PFS was the 
interval from the first day of each line of chemotherapy until
documented progression or death from any cause and was
censored on the date of the last follow-up visit for patients
who were still alive and whose disease had not progressed.
OS was measured from the first day of each line of chemo-
therapy until death or the final day of the follow-up period.
Toxicity was assessed using the National Cancer Institute
Common Terminology Criteria for Adverse Events ver. 3.0. 
4. Statistical analysis
Categorical variables were compared using chi-square
tests, and logistic regression was used to evaluate the corre-
lations. Survival was assessed using the Kaplan-Meier
method, and survival rates were compared using the 
log-rank test. Multivariate analysis of the independent prog-
nostic factors for survival was performed using the Cox 
proportional hazard regression model with a 95% confidence
interval. A p-value of < 0.05 was regarded as significant. 
Statistical analyses were performed using the SPSS ver. 17.0
(SPSS Inc., Chicago, IL).
Results
1. Patient characteristics
A total of 35 patients with advanced NSCLC who were
treated at Chungnam National University Hospital between
August of 2001 and December of 2013 were enrolled. The 
median age of the enrolled patients was 63 years, and there
were more males than females. The stage at initial diagnosis
was mostly IIIB and IV. Six patients with stage I to IIIA 
disease upon their initial diagnosis were recurrent cases.
Most patients had a favorable performance status (ECOG
performance scale, 0-2). Adenocarcinoma (60.0%) was the
most common histological type of cancer, followed by squa-
mous cell carcinoma (34.3%). Platinum/vinorelbine was 
administered to 17 patients as third-line chemotherapy and
to 18 patients as fourth- or fifth-line chemotherapy. The 
median follow-up duration was 7 months (range, 1 to 41
months). The most common previously treated regimen was
platinum/gemcitabine (34.8%) followed by platinum/doc-
etaxel (16.3%). Twenty-one patients (18 patients at the first-
line treatment; additional 3 patients at more than first-line
treatment) had shown response to the prior platinum-con-
taining regimens. The patients' characteristics are listed in
Table 1.
2. Efficacy
There was no complete response. A partial response was
observed in eight patients (response rate, 22.9%), and stable
disease was observed in 13 patients (disease control rate,
60.0%) (Table 2). Statistically significant higher response rates
were observed for patients who had shown a response to
previous chemotherapy compared with patients who had
not shown a response to previous chemotherapy (34.8%
[8/23] vs. 0% [0/12], p=0.020). However, no statistically 
significant differences in response rates were observed 
according to age, histologic subtype, or treatment line. A 
significantly higher disease control rate was observed for 
patients with adenocarcinoma (76.2% [16/21] vs. 35.7% [5/
14], p=0.017) and in females (100.0% [8/8] vs. 48.1% [13/27],
p=0.009). However, no statistically significant differences 
in disease control rates were observed according to age, 
performance status, or treatment and responsiveness to 
previous chemotherapy treatments.
Cancer Res Treat. 2015;47(4):638-644
640 CANCER  RESEARCH  AND  TREATMENT
Table 1. Patients’ baseline characteristics (n=35)
Characteristic No. (%)














Squamous cell carcinoma 12 (34.3)
Others 2 (5.7)
Smoking history




Fourth- or fifth-line 18 (51.4)





Pemetrexed alone 10 (10.9)
Docetaxel alone 10 (10.9)
Gefitinib 10 (10.9)
Others 13 (14.1)
Response rate to the prior 
platinum-containing regimens
First-line 18 (51.4)
More than first-line 3 (8.6)
Median follow-up duration (range, mo) 7 (1-41)
ECOG PS, Eastern Cooperative Oncology Group perform-
ance status.
Table 2. Response rate (n=35)
Best response No. (%)
Complete response 0 (
Partial response 8 (22.9)
Stable disease 13 (37.1)
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Fig. 1.  Progression-free survival for patients who received
platinum and vinorelbine as more than second-line
chemotherapy (n=35).
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3. Survival data
The median PFS was 4 months (95% CI, 2.1 to 5.8 months)
(Fig. 1). In univariate analysis, patients with good perform-
ance status, those with histologically classified adenocarci-
noma, and never-smokers had significantly longer PFS
(Table 3). The median OS was 10 months (95% CI, 1.0 to 41.0
months) (Fig. 2). In univariate analysis, patients with good
performance status, never-smokers, and those who had 
response over stable disease had significantly longer OS than
patients with poor performance status, smokers, and those
whose disease progressed after platinum/vinorelbine
chemotherapy (Table 4). However, in multivariate analysis,
there was no significant factor that influenced OS or PFS.
4. Toxicity
A total of 113 treatment cycles were administered. The 
median number of cycles per patient was 3 (range, 1 to 6).
The mean dose intensity of the treatment regimen was 94.7%
for both cisplatin and vinorelbine. The most common toxici-
Table 3. Progression-free survival in univariate and multivariate analysis (n=35)
Variable Median (95% CI) p-value 
Univariate Multivariate 
Age (yr) 0.090 -
< 65 2.0 (1.5-2.4)








" IIIB 4.0 (2.3-5.6)
IV 4.0 (0.6-5.3)
ECOG PS 0.030 0.780 (HR, 0.8; 95% CI, 0.8-3.5)
0 or 1 4.5 (2.6-6.3)
2 or 3 2.0 (0.8-3.1)
Smoking history 0.046 0.144 (HR, 1.7; 95% CI, 0.8-3.5)
Never 4.5 (3.0-5.9)
Former and current 2.0 (0.1-3.8)
Treatment line 0.719 -
Third-line 2.0 (0.7-3.2)
Fourth- and fifth-line 4.0 (2.6-5.3)
Responsiveness for the previous treatment 0.358 -
Response 4.0 (1.0-6.9)
No response 2.0 (0.0-4.1)
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Fig. 2.  Overall survival for patients who received plat-
inum and vinorelbine as more than second-line chemoth-
erapy (n=35).
ties were fatigue (41.6%) and peripheral neuropathy (24.8%);
however, these side effects were tolerable. As shown in Table 5,
other side effects included neutropenia, febrile neutropenia,
anemia, thrombocytopenia, nausea/vomiting, and diarrhea;
however, the incidences of these were low.
Discussion
Due to recent advances in treatment of advanced NSCLC
and supportive care, the patient population requiring subse-
quent chemotherapy is increasing [10,11]. Asahina et al. [1]
reported that nearly 38% of patients with advanced NSCLC
who received first-line chemotherapy went on to receive
third-line chemotherapy, and the authors emphasized the
need for randomized controlled trials for third-line treat-
Cancer Res Treat. 2015;47(4):638-644
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Table 4. Overall survival in univariate and multivariate analysis (n=35)
Variable Median (95% CI) p-value 
Univariate Multivariate 
Age (yr) 0.929 -
< 65 7.0 (1.9-12.0)








" IIIB 10.0 (0.0-21.8)
IV 7.0 (1.8-12.1)
ECOG PS 0.020 0.116 (HR, 0.4; 95% CI, 0.1-1.2)
0 or 1 14.0 (3.7-24.2)
2 or 3 4.0 (1.7-6.2)
Smoking history 0.049 0.339 (HR, 1.7; 95% CI, 0.6-4.8)
Never 18.5 (3.8-33.1)
Former and current 6.0 (3.9-8.0)
Treatment line 0.492 -
Third-line 7.0 (6.0-7.9)
Fourth- and fifth-line 18.5 (2.7-34.2)
Responsiveness for the previous treatment 0.774 -
Response 14.0 (0.9-27.0)
No response 6.5 (5.1-7.8)
Responsiveness for the current treatment 0.014 0.05 (HR, 0.4; 95% CI, 0.1-1.0)
Disease controlled 18.5 (4.9-32.0)
Not controlled 4.0 (1.6-6.3)
CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio.
Table 5. Toxicities (n=113 cycles)
Grade 1 2 3 4
Neutropenia - 3 (2.7) 6 (5.3) 9 (8.0)
Febrile neutropenia - - - 3 (2.7)
Anemia - 8 (7.1) 9 (8.0) -
Thrombocytopenia 1 (1.0) 2 (1.8) 2 (1.8) 1 (1.0)
Mucositis 2 (1.8) 3 (2.7) - -
Nausea 2 (1.8) 7 (6.2) 3 (2.7) -
Vomiting 1 (1.0) 3 (2.7) 4 (3.5) -
Fatigue 6 (5.3) 47 (41.6) - 2 (1.8)
Peripheral neuropathy 1 (1.0) 28 (24.8) - -
Constipation - 3 (2.7) - -
Diarrhea - 2 (1.8) 1 (1.0) -
Values are presented as number (%).
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ments. Girard et al. [2] reported that approximately 28% of
patients received a third-line treatment; the authors sug-
gested that patients who showed good performance statuses
and had good disease control rates after their previous treat-
ments may benefit from third-line treatment. 
In this retrospective study, platinum/vinorelbine, when
used as treatment regimen beyond second-line chemother-
apy, was effective in patients with advanced NSCLC, and the
toxicity was tolerable. Despite the availability of many new
active agents for NSCLC, the reported response rates beyond
second-line systemic therapy have generally been less than
20%. In the case of erlotinib as a third or fourth line of treat-
ment in advanced NSCLC cases, the response rate was 8.9%
in a randomized, controlled study [4]. In two other retrospec-
tive studies, the objective response rate was 10%-20%, and
the OSs from third-line and fourth-line pemetrexed treat-
ments were 11.0 and 13.0 months, respectively [12,13]. 
Single-agent vinorelbine as a third-line chemotherapy for 
advanced NSCLC had limited activity, as reported by Kanat
et al. [14]; there was no partial response, and the median OS
was approximately 3.5 months. However, in our study, the
objective response rate of platinum/vinorelbine was 22.9%.
Patients who had shown a response to prior therapy tended
to have a good response, which was also similar to a report
by Girard et al. [2], who demonstrated that the performance
status and disease control after the first and second lines of
treatment can be used as prognostic factors.
In our study, the survival data showed that the median
PFS was 4 months, and that the median OS was 10 months.
These findings are similar to the survival data for peme-
trexed treatment beyond second-line therapy. Chang et al.
[12] reported that the median PFS was 3.2 months, and the
median OS was 11.6 months for third- and fourth-line peme-
trexed treatments. Sun et al. [13] reported that the median
PFS was 3.0 months and response rate was 12% for third-line
pemetrexed treatment. We performed subgroup analyses for
PFS and OS for evaluation of predictive factors for better 
outcome with platinum/vinorelbine therapy.
According to univariate analyses, the strong predictive 
factors were good performance status (ECOG performance
scale, 0-1), never-smoker status, and responsiveness to the
previous treatment. However, none of these factors main-
tained significance in multivariate analyses, which might be
due to the small number of patients in this study. According
to Sun et al. [13], good performance status was still a strong
predictive factor in multivariate analysis.
And the toxicities of platinum/vinorelbine at more than
second-line chemotherapy were quite tolerable. Compared
to previous reports, the lower incidence of adverse events,
particularly peripheral neuropathy, in this study might have
arisen from the retrospective collection of the data [8,9]. Four
cycles of platinum-based combination chemotherapy is 
usually used, thus the dose limit of cisplatin is not reached
at first-line treatment. Therefore, we can use this platinum
plus vinorelbine regimen as more than second-line
chemotherapy in patients showing response to prior plat-
inum containing regimen.
As a result of the increased understanding of the molecular
pathogenesis of NSCLC and the introduction of new targeted
agents, treatment of NSCLC has developed rapidly [15]. 
In particular, the presence of certain gene alterations (e.g.,
EGFRmutations or ALK gene rearrangement) affect decision-
making for initial treatment. However, some studies have 
reported predictive biomarkers of the response to cytotoxic
chemotherapy in NSCLC. Vinolas et al. [16] demonstrated
that a single nucleotide polymorphism in the MDR1 gene
was associated with chemosensitivity in patients treated with
cisplatin plus vinorelbine. Therefore, there remains a need
for identification of biomarkers for predicting the treatment
outcome of platinum plus vinorelbine.
Conclusion
In conclusion, platinum plus vinorelbine may be a good
therapeutic option as a third or higher line of treatment for
advanced NSCLC, particularly in patients who responded to
prior treatments and show a good performance status. In 
addition, more large prospective studies will be needed in
order to confirm the efficacy and safety of platinum plus 
vinorelbine as a third or higher line of treatment.
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